Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last €31.73 EUR
Change Today -0.361 / -1.12%
Volume 0.0
HAZ On Other Exchanges
Symbol
Exchange
New York
Frankfurt
As of 9:32 AM 08/28/15 All times are local (Market data is delayed by at least 15 minutes).

haemonetics corp/mass (HAZ) Snapshot

Open
€31.78
Previous Close
€32.10
Day High
€31.78
Day Low
€31.73
52 Week High
03/13/15 - €42.77
52 Week Low
09/23/14 - €26.28
Market Cap
1.6B
Average Volume 10 Days
0.0
EPS TTM
--
Shares Outstanding
50.9M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for HAEMONETICS CORP/MASS (HAZ)

Related News

No related news articles were found.

haemonetics corp/mass (HAZ) Related Businessweek News

No Related Businessweek News Found

haemonetics corp/mass (HAZ) Details

Haemonetics Corporation designs, manufactures, and markets blood management solutions. The company operates through North America Plasma, North America Blood Center and Hospital, Europe, Asia Pacific, and Japan segments. It offers plasma collection and storage products, including PCS brand plasma collection equipment and disposables, plasma collection containers, and intravenous solutions, as well as information technology platforms for plasma customers to manage their donors, operations, and supply chain; Multicomponent Collection System brand apheresis equipment to collect specific blood components integrated from the donor; Automated Cell Processor brand solution to automate the washing and freezing of red cell components in the lab; and manual collection, filtration, and processing products. The company also offers hospital products comprising TEG thrombelastograph hemostasis analyzer systems that measure a patient's hemostasis or the ability to form and maintain blood clots; Cell Saver systems for cardiovascular surgeries; and OrthoPAT surgical blood salvage systems for orthopedic procedures. In addition, it provides IMPACT Online blood management portal to monitor the results of its new blood management practices; SafeTrace Tx that manages blood product inventory and transfusions, and performs patient cross-matching; BloodTrack to manage tracking and control of blood products from the hospital blood center; and SafeTrace and El Dorado Donor donation and blood unit management systems, as well as Hemasphere, Donor Doc, and e-Donor software solutions. The company markets and sells its products to bio-pharmaceutical companies, blood collection groups and independent blood centers, hospitals and hospital service providers, group purchasing organizations, and national health organizations through its direct sales force, as well as independent distributors. Haemonetics Corporation was founded in 1971 and is headquartered in Braintree, Massachusetts.

3,383 Employees
Last Reported Date: 05/22/15
Founded in 1971

haemonetics corp/mass (HAZ) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $640.2K
Chief Financial Officer and Executive Vice Pr...
Total Annual Compensation: $478.3K
Chief Operating Officer
Total Annual Compensation: $401.9K
Executive Vice President of Global Quality an...
Total Annual Compensation: $717.3K
Chief Science & Technology Officer
Total Annual Compensation: $441.0K
Compensation as of Fiscal Year 2015.

haemonetics corp/mass (HAZ) Key Developments

Haemonetics Corporation Unveils New HaemoCloud IoT Software Platform

Haemonetics Corporation has unveiled HaemoCloud, a new internet of things, or IoT, software platform designed to connect all Haemonetics devices and software. HaemoCloud is a foundational suite of products including HaemoCommunicator and HaemoCloud, which allow Haemonetics blood management devices to communicate with hospital information systems and provide real-time device operational data for service and support. This strategy embraces the Internet of Things to create smart, safe, connected products that will improve the level of care and drive down costs across the entire blood value chain. HaemoCommunicator works within an institution to format and transfer data from diagnostic thromboelastography (i.e., TEG 6s) and cell salvage devices (i.e., Cell Saver Elite). Operational data from the device is also managed by HaemoCommunicator to provide lab and IT staff real-time access to device performance. On a nightly basis, each HaemoCommunicator installation compiles device performance data and transfers it to HaemoCloud allowing Haemonetics' customers and support organizations to monitor the use and performance of each device. HaemoCommunicator is designed to integrate with both Haemonetics and competitive devices, to create a seamless data experience for customers.

Haemonetics Corporation Announces Executive Changes

On July 29, 2015 Peter Allen resigned as President, Global Plasma at Haemonetics Corporation to pursue other opportunities. Thomas McCurdy, who has served as Vice President, North America Patient Sales since 2010, has been appointed as Mr. Allen's successor, effective immediately.

Haemonetics Corporation Reports Unaudited Consolidated Earnings Results for the First Quarter Ended June 27, 2015; Reaffirms Earnings Guidance for the Fiscal Year 2016

Haemonetics reported unaudited consolidated earnings results for the first quarter ended June 27, 2015. For the quarter, the company reported net revenues of $213.413 million against $224.488 million a year ago. Operating income was $3.606 operating loss of $1.666 million a year ago. Income before taxes was $1.597 million against loss before taxes of $4.209 million a year ago. Net loss was $0.267 million against $3.649 million a year ago. Net loss per common share assuming dilution was $0.01 million against $0.07 million a year ago. Net cash provided by operating activities was $9.250 million against $13.738 million a year ago. Capital expenditures on property, plant and equipment was $24.246 million against $37.085 million a year ago. Non-GAAP operating income was $25.827 million against $28.778 million a year ago. Non-GAAP income before taxes was $23.818 million against $26.458 million a year ago. Non-GAAP net income was $17.984 million against $19.725 million a year ago. Non-GAAP net income per common share assuming dilution was $0.35 against $0.38 a year ago. The Company reported free cash flow, before transformation and restructuring costs, of $1 million in the first quarters of fiscal 2016 and 2015. The company reaffirmed its previous fiscal 2016 guidance for revenue growth of 4-6%, implying a range of $946.5 million to $965 million. The company continues to expect approximately 46% of revenue in the first half and 54% in the second half of the fiscal year. The company reaffirmed full year adjusted earnings per share in the range of $1.98 to $2.08, representing 7% to 12% earnings growth over fiscal 2015. The company continues to expect approximately 35% of fiscal 2016 earnings to be realized in the first half of the year and 65% in the second half. Free cash flow guidance for fiscal 2016 is reaffirmed in the range of $105 million to $110 million before funding approximately $27 million of capital expenditures and cash transformation expenditures to complete the VCC initiatives. Acquisition related amortization is expected to approximate $30 million, or $0.40 per share, and is excluded from adjusted operating income and adjusted earnings per share. Full year guidance is for adjusted gross margin to average between 48% and 49%, adversely affected by mix and currency and positively affected by VCC and other structural cost improvements. Adjusted operating margin is expected to average between 15% to 16%. In constant currency, the company is reaffirming the company fiscal 2016 earnings growth rate of 15% to 20%.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
HAZ:GR €31.73 EUR -0.361

HAZ Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Fresenius SE & Co KGaA €62.76 EUR -0.96
Medtronic PLC $73.56 USD +0.04
Terumo Corp ¥3,340 JPY +85.00
View Industry Companies
 

Industry Analysis

HAZ

Industry Average

Valuation HAZ Industry Range
Price/Earnings 92.2x
Price/Sales 2.1x
Price/Book 2.3x
Price/Cash Flow 90.2x
TEV/Sales 1.4x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact HAEMONETICS CORP/MASS, please visit www.haemonetics.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.